undamentalytics Newsletter
Sign in

Hedge fund

Braidwell LP

13F for the quarter to June 30, 2026, filed August 14, 2026 · SEC CIK 1920938

Reported value
$2.6bn
98% in companies we cover
Positions we cover
77
Largest CAI 5.7%
Copy, a year
+16.1%
S&P 500 +19.7%
Copy Sharpe ratio
0.52
S&P 500 1.02

How copying its 13F would have done

$10.0k$20.0k 2023202420252026 $19.5k$17.4k
CopyS&P 500 $10,000 copying Braidwell LP's filed holdings in companies we cover from February 17, 2023, buying on the first trading day after each 13F was filed and holding until the next, against the S&P 500 (total return). Marked weekly, log scale. Before costs and taxes; misses trading within each quarter and anything 13F does not show (shorts, cash, bonds, non-US holdings).

Biggest drop −35.4% (S&P 500 −16.9%); beta 1.09; alpha −2.0% a year (t = −0.19); last 12 months +43.1% against +12.1%.

Reported value by quarter

Braidwell LP: 13F reported value Total value of all positions in each quarter's 13F, as filed (values before 2023 were filed in thousands of dollars and are converted).
$0 $500B $1T $1.5T $2T Reported value, 2022-12-31: $1.7T Reported value, 2023-03-31: $1.6B Reported value, 2023-06-30: $1.7B Reported value, 2023-09-30: $1.6B Reported value, 2023-12-31: $1.3B Reported value, 2024-03-31: $1.8B Reported value, 2024-06-30: $2B Reported value, 2024-09-30: $2.3B Reported value, 2024-12-31: $2.2B Reported value, 2025-03-31: $1.9B Reported value, 2025-06-30: $2.1B Reported value, 2025-09-30: $2.5B Reported value, 2025-12-31: $2.6B Reported value, 2026-03-31: $2.6B Reported value, 2026-06-30: $2.6B 2022-12-31 2023-09-30 2024-06-30 2025-03-31 2026-06-30 $2.6B
View chart data
Period Reported value
2022-12-31 $1.7T
2023-03-31 $1.6B
2023-06-30 $1.7B
2023-09-30 $1.6B
2023-12-31 $1.3B
2024-03-31 $1.8B
2024-06-30 $2B
2024-09-30 $2.3B
2024-12-31 $2.2B
2025-03-31 $1.9B
2025-06-30 $2.1B
2025-09-30 $2.5B
2025-12-31 $2.6B
2026-03-31 $2.6B
2026-06-30 $2.6B

Holdings and moves

CompanyShare of portfolioValueSharesChange in shares
CAICaris Life Sciences, Inc.5.65%$147.1m8.26M+3.1% Added
HNGEHinge Health, Inc.4.24%$110.4m1.33M−8.6% Reduced
GKOSGlaukos Corp3.18%$82.7m591.9K−22.5% Reduced
EWTXEdgewise Therapeutics, Inc.3.12%$81.1m2.00M−14.9% Reduced
SYRESpyre Therapeutics, Inc.3.00%$78.1m879.5K−5.7% Reduced
IRTCIrhythm Holdings, Inc.2.99%$77.8m654.3K+7.2% Added
NEONeogenomics Inc2.76%$71.8m4.92M−12.4% Reduced
KODKodiak Sciences Inc.2.67%$69.6m1.79M−1.7% Reduced
XENEXenon Pharmaceuticals Inc.2.62%$68.3m1.13M−15.5% Reduced
GLUEMonte Rosa Therapeutics, Inc.2.28%$59.3m2.45M−23.5% Reduced
DNTHDianthus Therapeutics, Inc.2.23%$58.0m594.6K−33.9% Reduced
NBIXNeurocrine Biosciences Inc2.18%$56.7m336.2K−48.4% Reduced
ATECAlphatec Holdings, Inc.2.17%$56.5m6.53M+200.6% Added
GENBGenerate Biomedicines, Inc.2.13%$55.4m3.28M−8.6% Reduced
MRVIMaravai Lifesciences Holdings, Inc.2.09%$54.3m8.70M−15.0% Reduced
KRYSKrystal Biotech, Inc.1.84%$47.9m129.0K−29.3% Reduced
HUMHumana1.75%$45.5m114.5KNew
TMOThermo Fisher Scientific1.72%$44.8m89.4K−3.8% Reduced
KYMRKymera Therapeutics, Inc.1.67%$43.4m378.2K+12.0% Added
RYTMRhythm Pharmaceuticals, Inc.1.63%$42.3m381.1K+22.7% Added
ACADAcadia Pharmaceuticals Inc1.60%$41.7m1.65M−33.4% Reduced
BTSGBrightspring Health Services, Inc.1.60%$41.6m596.8K−41.3% Reduced
TMDXTransmedics Group, Inc.1.55%$40.5m609.7K+85.1% Added
MBXMBX Biosciences, Inc.1.51%$39.2m710.9K−52.4% Reduced
CLYMClimb Bio, Inc.1.40%$36.5m2.80M+82.9% Added
CDNACaredx, Inc.1.34%$34.8m1.22M−43.8% Reduced
MAZEMaze Therapeutics, Inc.1.31%$34.0m1.14MNew
DRUGBright Minds Biosciences Inc.1.30%$34.0m483.8K−10.4% Reduced
ACHCAcadia Healthcare Company, Inc.1.29%$33.7m1.14M+76.7% Added
NKTRNektar Therapeutics1.27%$33.1m473.6K+112.7% Added
CRVSCorvus Pharmaceuticals, Inc.1.22%$31.8m2.13M+21.3% Added
NRIXNurix Therapeutics, Inc.1.20%$31.2m1.29M−26.5% Reduced
INSPInspire Medical Systems, Inc.1.16%$30.2m677.6K0.0%
AVTXAvalo Therapeutics, Inc.1.16%$30.1m1.63MNew
ALMRAlamar Biosciences, Inc.1.13%$29.4m1.08MNew
DHRDanaher Corporation1.10%$28.7m150.6K+8.1% Added
ISRGIntuitive Surgical1.07%$27.9m70.1K−9.3% Reduced
ORKAOruka Therapeutics, Inc.1.02%$26.5m278.2KNew
AVLNAvalyn Pharma Inc.1.01%$26.4m801.4KNew
AVAHAveanna Healthcare Holdings, Inc.1.01%$26.3m3.07M+39.1% Added
BIOABioage Labs, Inc.0.97%$25.3m1.03M−13.9% Reduced
BSXBoston Scientific0.96%$25.1m587.6K+69.6% Added
VERAVera Therapeutics, Inc.0.93%$24.2m564.7K+7.8% Added
RGENRepligen Corp0.93%$24.2m177.1K+272.8% Added
ZURAZura Bio Ltd0.90%$23.5m3.98M−0.2%
GHGuardant Health, Inc.0.85%$22.2m147.8K−70.4% Reduced
EOLSEvolus, Inc.0.84%$21.9m3.16M+1.6% Added
NTRANatera, Inc.0.83%$21.6m79.5K−38.4% Reduced
KIDSOrthopediatrics Corp0.81%$21.1m1.10M0.0%
ELVElevance Health0.80%$20.9m54.0K−13.1% Reduced
TECXTectonic Therapeutic, Inc.0.79%$20.5m596.9K−29.5% Reduced
DYNDyne Therapeutics, Inc.0.79%$20.5m921.6K−45.2% Reduced
IMCRImmunocore Holdings plc0.64%$16.6m521.3KNew
ARGXArgenx SE0.63%$16.4m17.7K−79.2% Reduced
CLDXCelldex Therapeutics, Inc.0.62%$16.2m436.6K−67.8% Reduced
OVIDOvid Therapeutics Inc.0.61%$15.9m5.92MNew
MNKDMannkind Corp0.57%$14.7m3.46MNew
QUREUniqure N.V.0.53%$13.9m301.7KNew
XFORX4 Pharmaceuticals, Inc0.52%$13.6m2.92M−10.7% Reduced
ORICOric Pharmaceuticals, Inc.0.51%$13.2m1.21M+7.7% Added
KNSAKiniksa Pharmaceuticals International, plc0.45%$11.8m183.8K−32.5% Reduced
OCSOculis Holding AG0.44%$11.6m834.2KNew
ACRSAclaris Therapeutics, Inc.0.43%$11.3m2.14M+26.1% Added
SPTXSeaport Therapeutics, Inc.0.42%$10.9m500.0KNew
VORVor Biopharma Inc.0.41%$10.6m573.1K+22.8% Added
SRZNSurrozen, Inc.0.39%$10.1m390.8K−1.3% Reduced
IMUXImmunic, Inc.0.38%$9.9m645.0KNew
IONSIonis Pharmaceuticals Inc0.36%$9.3m116.8K−10.8% Reduced
DGXQuest Diagnostics0.35%$9.2m43.2KNew
ANLAdlai Nortye Group Ltd.0.35%$9.1m795.2KNew
TENXTenax Therapeutics, Inc.0.33%$8.5m584.4KNew
KARDKardigan, Inc.0.28%$7.2m300.0KNew
COAGHemab Therapeutics Holdings, Inc.0.23%$5.9m160.0KNew
GHRSGH Research PLC0.21%$5.6m207.2KNew
WATWaters Corporation0.20%$5.3m14.0KNew
RACCResearch Alliance Corp III0.16%$4.3m400.0KNew
LUNGPulmonx Corp0.04%$978,303752.5K0.0%
CompanyBought (value)Shares
HUMHumana$45.5m114.5K
ATECAlphatec Holdings, Inc.$37.7m4.36M
MAZEMaze Therapeutics, Inc.$34.0m1.14M
AVTXAvalo Therapeutics, Inc.$30.1m1.63M
ALMRAlamar Biosciences, Inc.$29.4m1.08M
ORKAOruka Therapeutics, Inc.$26.5m278.2K
AVLNAvalyn Pharma Inc.$26.4m801.4K
TMDXTransmedics Group, Inc.$18.6m280.3K
RGENRepligen Corp$17.7m129.6K
NKTRNektar Therapeutics$17.5m250.9K
IMCRImmunocore Holdings plc$16.6m521.3K
CLYMClimb Bio, Inc.$16.5m1.27M
OVIDOvid Therapeutics Inc.$15.9m5.92M
MNKDMannkind Corp$14.7m3.46M
ACHCAcadia Healthcare Company, Inc.$14.6m495.6K

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanySold (value)Shares
CGONCG Oncology, Inc.−$66.7m−984.8K
ARGXArgenx SE−$62.4m−67.2K
NBIXNeurocrine Biosciences Inc−$53.2m−315.9K
GHGuardant Health, Inc.−$52.8m−351.9K
MBXMBX Biosciences, Inc.−$43.1m−781.6K
PENPenumbra Inc−$34.6m−105.4K
CLDXCelldex Therapeutics, Inc.−$34.2m−919.4K
DNTHDianthus Therapeutics, Inc.−$29.7m−304.8K
BTSGBrightspring Health Services, Inc.−$29.3m−419.8K
ILMNIllumina, Inc.−$28.3m−229.2K
BMRNBiomarin Pharmaceutical Inc−$28.1m−497.0K
CDNACaredx, Inc.−$27.1m−952.5K
ESTAEstablishment Labs Holdings Inc.−$26.3m−463.6K
FULCFulcrum Therapeutics, Inc.−$24.0m−3.13M
GKOSGlaukos Corp−$24.0m−171.6K

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanyValue last quarterShares
CGONCG Oncology, Inc.$66.7m984.8K
PENPenumbra Inc$34.6m105.4K
ILMNIllumina, Inc.$28.3m229.2K
BMRNBiomarin Pharmaceutical Inc$28.1m497.0K
ESTAEstablishment Labs Holdings Inc.$26.3m463.6K
FULCFulcrum Therapeutics, Inc.$24.0m3.13M
CVSCVS Health$20.9m290.7K
TARSTarsus Pharmaceuticals, Inc.$18.6m265.7K
TGTXTG Therapeutics, Inc.$11.9m358.8K
CNCCentene Corporation$10.8m330.0K
CMPXCompass Therapeutics, Inc.$10.4m1.97M
RVMDRevolution Medicines, Inc.$8.3m84.9K
GRALGrail, Inc.$7.4m142.8K
DNLIDenali Therapeutics Inc.$5.7m296.3K
HROWHarrow, Inc.$5.5m156.4K
RVTYRevvity$4.2m48.4K
CELCCelcuity Inc.$3.3m29.2K
PRAXPraxis Precision Medicines, Inc.$3.2m10.0K
  • Health Care100.0%

Share of the value held in companies we cover, by sector.

PeriodCopy, a yearS&P 500SharpeS&P 500Biggest dropBeta
Whole backtestFebruary 17, 2023 to November 2, 2026+16.1%+19.7%0.521.02−35.4%1.09
Last three yearsNovember 3, 2023 to November 2, 2026+25.1%+21.8%0.821.16−35.4%1.05
Last yearNovember 7, 2025 to November 2, 2026+47.5%+14.2%1.510.84−10.6%0.88

From SEC Form 13F data sets. A 13F lists long positions in US-listed shares at the quarter's end, filed up to 45 days later; it does not show shorts, cash, bonds, non-US holdings or trades within the quarter. Positions in companies outside our coverage are not listed here. Research, not investment advice.